Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS Could Streamline Coverage For Breakthrough Medtech Under House Proposal

Executive Summary

Newly introduced bill would seek to smooth the Medicare coverage and reimbursement pathway for breakthrough devices.

You may also be interested in...



Lawmakers Press CMS To Enact MCIT Breakthrough Device Coverage Rule

The Medicare rule, which was delayed by 60 days under a broader regulatory freeze, is seen as critical to the reimbursement of innovative devices.

Medtech Firms Focus Campaign Dollars On Device Bill Proponents, Excise Tax Opponents In 2018

For the 2018 midterm elections in the United States, the most generous medtech company donations went to politicians who introduced or cosponsored pro-device legislation or made it clear they oppose the medtech excise tax and want it permanently removed, according this Medtech Insight analysis of industry campaign contributions leading up to the election.

CMS Actively Looking For New Reimbursement Pathway For Innovative Devices

Industry is looking for a policy by the end of the year that would provide an automatic, temporary coverage pathway for breakthrough devices, and federal officials, including from the US Centers for Medicare and Medicaid Services (CMS) acknowledge they are actively looking at options for improving device reimbursement.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT122788

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel